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Abstract
Background: A characteristic feature of atherosclerosis is its diffuse involvement of arteries across the entire human body.
Bone marrow cells (BMC) can be simultaneously transferred with therapeutic genes and magnetic resonance (MR) contrast
agents prior to their transplantation. Via systemic transplantation, these dual-transferred BMCs can circulate through the
entire body and thus function as vehicles to carry genes/contrast agents to multiple atherosclerosis. This study was to
evaluate the feasibility of using in vivo MR imaging (MRI) to monitor BMC-mediated interleukin-10 (IL-10) gene therapy of
atherosclerosis.
Methodology: For in vitro confirmation, donor mouse BMCs were transduced by IL-10/lentivirus, and then labeled with a T2-
MR contrast agent (Feridex). For in vivo validation, atherosclerotic apoE
2/2 mice were intravenously transplanted with IL-10/
Feridex-BMCs (Group I, n=5) and Feridex-BMCs (Group II, n=5), compared to controls without BMC transplantation (Group
III, n=5). The cell migration to aortic atherosclerotic lesions was monitored in vivo using 3.0T MRI with subsequent histology
correlation. To evaluate the therapeutic effect of BMC-mediated IL-10 gene therapy, we statistically compared the
normalized wall indexes (NWI) of ascending aortas amongst different mouse groups with various treatments.
Principal Findings: Of in vitro experiments, simultaneous IL-10 transduction and Feridex labeling of BMCs were successfully
achieved, with high cell viability and cell labeling efficiency, as well as IL-10 expression efficiency ($90%). Of in vivo
experiments, MRI of animal groups I and II showed signal voids within the aortic walls due to Feridex-created artifacts from
the migrated BMCs in the atherosclerotic plaques, which were confirmed by histology. Histological quantification showed
that the mean NWI of group I was significantly lower than those of group II and group III (P,0.05).
Conclusion: This study has confirmed the possibility of using MRI to track, in vivo, IL-10/Feridex-BMCs recruited to
atherosclerotic lesions, where IL-10 genes function to prevent the progression of atherosclerosis.
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Introduction
Atherosclerotic cardiovascular disease remains the leading cause
of death in developed countries. A characteristic feature of
atherosclerotic cardiovascular disease is its diffuse involvement of
arteries across the entire human body, with the presence of multiple
atherosclerotic lesions. Endovascular interventional procedures,
such as balloon angioplasty and stenting, are currently used as
routine ‘‘local’’ treatments of atherosclerotic arteries. However,
these interventional approaches do not treat multiple and diffuse
atherosclerosis. Thus, it is essential to seek alternatives, to meet the
need of simultaneously treating all atherosclerotic arteries at once.
Recent studies have confirmed that bone marrow (BM)-derived
stem-progenitor cells (SPC) can give rise to vascular progenitor
cells that migrate or home to atherosclerotic arteries and
differentiate into either smooth muscle cells (SMC) or endothelial
cells (EC) [1–4]. Intravenously-transfused hematopoietic SPCs
circulate in the blood system, flow through the entire body, and
thereby can reach all atherosclerotic arteries. Thus, the charac-
teristic of circulating SPCs with wide dissemination through the
entire body may provide an appropriate approach for cell-
mediated therapy of multiple and diffuse atherosclerosis.
Gene therapy is an exciting frontier in cardiovascular medicine
[5–7]. Recent studies have confirmed that one of the anti-
inflammatory genes, interleukin-10 (IL-10), is a crucial protective
factor against the progression of atherosclerotic disease [8–10].
The transfer of IL-10 genes into hematopoietic SPCs prior to their
transplantation to the body may allow for the simultaneous
treatment of diffuse and multiple atherosclerotic lesions through
the SPC-mediated, plaque-specific delivery of IL-10 genes.
Recent efforts using magnetic resonance imaging (MRI) to
serially track cell transplantation have focused on labeling stem
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paramagnetic iron oxide agents [11]. Once magnetically labeled,
stem cells may carry MR contrast agents specifically to the targets
and thus be visualized under MRI [12–14]. The two concepts, that
(a) hematopoietic SPCs can be simultaneously transferred with
therapeutic genes and MR contrast agents prior to their
transplantation; and (b) the dual-transferred hematopoietic SPCs
can circulate through the body and thus function as vehicles to
carry genes/contrast agents to the atherosclerotic plaques,
motivated us to develop a plaque-specific MRI technique, to
monitor SPC-mediated vascular gene therapy. The aim of this
study was to confirm the possibility of using in vivo MRI to
monitor IL-10 gene-transduced, MR contrast agent-labeled bone
marrow cells (BMC) that were recruited to atherosclerosis for
preventing the progression of atherosclerotic disease.
Materials and Methods
Study design
This study was divided into three phases. Phase I included a
series of in vitro experiments to confirm the feasibility of
simultaneous IL-10 gene transduction and Feridex labeling of
BMCs, with determination of the cell viability and cell labeling
efficiency, as well as IL-10 gene expression efficiency. Phase II
included a series of in vivo experiments to validate the feasibility of
using MRI to track the gene/contrast agent dual-modified BMCs
migrated to atherosclerotic lesions, which was confirmed by
subsequent MR-histology correlation. Phase III focused on
histologic evaluation of the role of BMC-mediated IL-10 gene
therapy in preventing the progression of atherosclerotic plaques.
The animal protocol for this study was approved by University of
Washington’s Institutional Animal Care and Use Committee
(Protocol Number: 4120-01) and complied with National Institutes
of Health guidelines [15].
In Vitro Experiments
MIL-10-lentivirus production. A lentivirus-based plasmid
was made by inserting the mIL-10 cDNA into the pLenti6.3/V5-
TOPO vector (Invitrogen, Carlsbad, CA, USA) (Fig. 1). This
pLenti-mIL-10 plasmid was then used to transfect 293FT cells
with a Packaging Mix (pLP1, pLP2 and pLP-VSVG, Invitrogen)
to produce mIL-10 lentivirus.
BMC Extraction. BMCs were extracted from seven C57/BL
donor mice (six weeks old, Harlan Laboratories, Inc., Kent, WA,
USA) by using the previously-established protocol [12,13]. Briefly,
the femurs and tibias of donor mice were excised. Then, the
marrow was aspirated using a syringe with a 28-gauge needle and
collected in a tube. After lysing red blood cells with human RBC
lysis buffer (Boston Bioproducts, Worcester, MA, USA), the
purified BMCs were washed with phosphate-buffered saline (PBS).
IL-10 transduction and Feridex-labeling of BMCs. Ac-
cording to the manufacturer’s protocol (Invitrogen, Carlsbad, CA,
USA), we first transduced the donor BMCs with lentiviral vectors
that carried the IL-10 genes. The transduction of BMCs was
performed at multiplicity of infection=1, using several agents of
QBSF 58 serum-free medium (Quality Biological Inc.
Gaithersburg, MD, USA), 8-ug/ml polybrene (Sigma, St. Louis,
MO, USA), 50-ug/ml mSCF, 50-ug/ml hFlt3, and 20-ug/ml
hTPO (PeproTech Inc. Rocky Hill, NJ, USA) for 48 hours.
After transduction, the IL-10-BMCs were labeled with a
superparamagnetic iron oxide MR contrast agent (25-ug Fe/ml,
Feridex I.V.; Berlex Laboratories, Inc., Wayne, NJ, USA) and a
poly-cation transduction agent (375 ng/ml, Poly-L-lysine; Sigma,
St. Louis, MO, USA). We also set different control groups,
including (i) Feridex-labeled BMCs; (ii) IL-10-transduced BMCs;
and (iii) unmodified BMCs. The in vitro experiments for each of the
cell groups were performed in triplicate.
Laboratory Confirmation. Successful simultaneous trans-
duction and labeling of BMCs were confirmed by immuno-
histochemical (IHC) staining for IL-10 gene expression and Prussian
blue staining for Feridex labeling. IHC was performed with a primary
goat monoclonal antibody against mouse IL-10 (Sigma, St. Louis,
MO, USA) using an anti-goat HPR-DAB cell & tissue staining kit
according to the manufacturer’s specification (R&D Systems, Inc.,
Minneapolis, MN, USA). Cells were then counterstained with
hematoxylin (Ricca Chemical Company, Arlington, Texas, USA).
Prussian blue staining was performed by incubating para-
formaldehyde-fixed, Feridex–labeled BMCs with 2% potassium
ferrocyanide in 2% hydrochloric acid for 30 minutes. Cells were
then counterstained with eosin (Sigma Aldrich Inc., St. Louis, MO,
USA).
Evaluation of Cell Viability and Labeling Efficiency. Via-
bility of the transduced and labeled cells was determined by a
trypan blue exclusion assay with subsequent cell counting. The cell
labeling/gene transduction efficiencies were determined by
percentages of Feridex-positive cells (as intracellular blue-colored
dots with Prussian blue staining) and IL-10 positive cells (as
intracellular brown-colored precipitates with IHC), which were
counted in three fields of each cell study group under a microscope
(Olympus BX51, Tokyo, Japan).
In Vivo Validation
Animal Study Groups and Cell Transplantation. Figure 2
summarizes the experimental design and steps of the in vivo
validation study. Fifteen recipient atherosclerotic apolipo-
protein E knockout (apoE
2/2) mice (8 weeks old, B6.129P2;
Jackson Laboratory, Bar Harbor, Maine, USA) were divided
Figure 1. Schematic diagram of construction of IL-10/Lentivi-
rus. IL-10/lentivirus-based plasmid was made by inserting the mIL-10
cDNA into the pLenti6.3/V5-TOPO vector.
doi:10.1371/journal.pone.0024529.g001
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transplantation (n=5), group II with Feridex-labeled BMC
transplantation (n=5), and group III with no cell
transplantation to serve as a control (n=5). All animals were
fed a high fat diet (15% butter and 2% cholesterol, RD Western
Diet; Research Diets, Inc., New Brunswick, NJ, USA) for
approximately three months [16].
Before BMC transplantations, ten recipient apoE
2/2 mice in
groups I and II were irradiated with a dose of 900 rads. Then, the
IL-10/Feridex BMCs or Feridex-labeled BMCs were transplanted
into the recipient mice via a tail vein injection. Each recipient
mouse received approximately 1610
7 cells suspended in 0.3 to
0.4 mL PBS. After cell transplantations, all animals were fed the
same high fat diet for additional four weeks.
In Vivo MRI. Approximately four weeks later, the aortic
atherosclerotic lesions of these apoE
2/2 mice were examined
using a 3T MRI scanner (Achieva, Philips Healthcare, Best, The
Netherlands). The mice were placed in a prone position within a
Philips solenoid mouse-specific coil (Philips Research, Hamburg,
Germany). Electrocardiogram (ECG)-gating (Model 1025
Monitoring & Gating System, SA Instruments, Inc., Stony
Brook, NY, USA) was performed via attaching two ECG
needles to the right-upper and left-lower extremities of the
mouse. Axial T2-weighted and proton density (PD)-weighted
black blood MR images of the ascending aorta were obtained
during the ventricular diastole by using a turbo spin-echo (TSE)
sequence, with T2-MRI parameters of repetition time (TR) at 4
heart beating intervals, 60-ms echo time (TE), 40640-mm field of
view (FOV), 9 TSE factor, 1-mm slice thickness with no slice gap,
1686162 matrix, and 8 signal average (NSA). PD-weighted MRI
parameters included TR at 4 heart beating intervals, 10-ms TE,
40640-mm FOV, 3 TSE factor, 1-mm slice thickness without slice
gap, 1686162 matrix, and 8 NSA.
Histologic Confirmation and Correlation. After achieving
satisfactory MR images, the animal was anesthetized by
intraperitoneal injection of 100–150 uL pentobarbital (0.25–
0.38 mg/g) and then exsanguinated by endovascular perfusion
with 4% paraformaldehyde via an open-chest, left cardiac ventricle
puncture approach. The ascending aorta, approximately 5 mm in
length measured from the cardiac base, was harvested, and then
serially cryosectioned at 6-mm slice thickness. Then, we stained the
slides with (a) Prussian blue staining for confirming Feridex-positive
cells; and (b) immunofluorescent dual staining for detecting dextran
shells of Feridex particles and IL-10 gene expression (Abcam,
Cambridge, MA, USA) in the atherosclerotic plaques. In addition,
DAPI (Vector Laboratories, Inc., Burlingame, CA, USA) was used
for nuclei staining. A previous study had extensively evaluated the
phenotypes of migrated BMCs localized in the atherosclerosis of the
same apoE
2/2 mouse model, and found them to primarily give rise
to smooth muscle cells [1]. Thus, in this study, we did not attempt to
determine if BMCs remained in undifferentiated form or followed
downstream differentiation pathways.
To evaluate the therapeutic effect of BMC-mediated IL-10 gene
therapy on preventing the progression of atherosclerotic plaques,
we used ImageJ (1.43 u, National Institutes of Health, Bethesda,
MD, USA) to quantitatively measure a normalized wall index
(NWI) of ascending aorta of each recipient apoE
2/2 mouse. NWI
was calculated by dividing the aortic wall area by the total aortic
area at cross-sectional views of digitized microscopic images [17].
The NWI provided a quantitative measure of atherosclerotic
plaque severity. The lower the NWI value is, the less severe the
atherosclerotic plaque is.
Figure 2. Schematic diagram of the experimental design and steps for the in vivo studies. These studies include (1) creating
atherosclerotic plaques in the ascending aorta of the recipient apoE
2/2 mouse by feeding a high fat diet; (2) extracting bone marrow cells (BMCs)
from the donor mouse; (3) co-transferring the donor BMCs with IL-10 gene and Feridex in vitro; (4) transplanting IL-10/Feridex-BMCs to the recipient
atherosclerotic mouse, which is irradiated prior to transplantation; (5) IL-10/Feridex-BMCs homing to aortic atherosclerotic plaques; (6) in vivo MRI
detecting Feridex-created signal voids from the recruited IL-10/Feridex BMCs in atherosclerotic plaques; and (7) confirming the successful recruitment
of co-transferred cells to the plaques by histology correlation.
doi:10.1371/journal.pone.0024529.g002
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formed by two investigators using SPSS 13.0 for Windows
(SPSS Inc., Chicago, IL, USA). A one-way ANOVA was used
to assess the significance of differences in the mean NWIs among
the three mouse groups with various treatments. A P value of less
than 0.05 was considered statistically significant.
Figure 3. Histologic examination of the in vitro experiments. (A–D) Prussian blue staining of (A) unmodified BMCs, (B) IL-10-transduced BMCs,
(C) Feridex-labeled BMCs, and (D) IL-10-transduced and Feridex-labeled BMCs. Feridex-positive cells represent with intracellular blue-colored dots (C
and D). (E–G) Immunohistochemical staining of (E) unmodified BMCs, (F) IL-10-transduced BMCs, and (G) IL-10-transduced and Feridex-labeled BMCs.
Intracellular IL-10 gene expression represents as intracellular brown-colored precipitates (F and G). 2006. Bar: 100 mm.
doi:10.1371/journal.pone.0024529.g003
Figure 4. Representative MRI-histologic correlation of atherosclerotic ascending aorta (insets) of apoE
2/2 mice. (A–D) ApoE
2/2 mice
with IL-10/Feridex-BMC transplantation. (E–H) ApoE
2/2 mice with Feridex-BMC transplantation. (I–L) ApoE
2/2 mice with no cell transplantation as a
control. (A, E, I) Proton-density-weighted (PDW) MRI shows thickening of the aortic walls due to formation of atherosclerotic lesions (arrows on A, E, I).
(B, F, J) T2-weighted MRI shows signal voids (arrows on B and F) at the aortic walls with Feridex-labeled and/or IL-10-transduced BMC transplantation,
where are not seen in the aortic wall of the control group (J). (C, G, K) Prussian blue staining shows the Feridex-positive BMCs migrated to the
atherosclerotic aortic walls (arrows in C and G), which are not visualized in the aortic wall of the control group (K). (D, H, L) Immunofluorescent dual
staining confirms simultaneous IL-10 gene expression (as red-colored spots, arrows on D), IL-10 overlap with dextran shells of Feridex particles (as
orange-colored dots, arrowheads on D) and dextran shells of Feridex particles (as green-colored dots, arrows on H), which are not seen in the aortic
wall of the control group (L). 4006. Bar: 100 mm. P=atherosclerotic plaque; M=medial. Blue color indicates nuclei.
doi:10.1371/journal.pone.0024529.g004
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Of in vitro experiments, the viability of IL-10/Feridex-BMCs
was 90%, while the viabilities for Feridex-BMCs and IL-10-BMCs
were 95%, in comparison to the 98% viability of the unmodified
BMCs. The efficiencies of Feridex labeling for the non-transduced
and IL-10-transduced BMCs were approximately 90% and 92%,
respectively. The efficiency of IL-10 gene transduction was 95%.
Prussian blue staining and IHC staining confirmed the successful
simultaneous IL-10 transduction and Feridex labeling of BMCs
(Fig. 3).
Of the in vivo experiments, T2-MRI of animal groups I and II
demonstrated signal voids of the aortic walls due to Feridex-
created artifacts from the migrated IL-10/Feridex-BMCs in
atherosclerotic lesions, which were confirmed as Feridex- and/or
IL-10-positive cells with immunofluorescent dual staining. These
findings were not seen in the control group III (Fig. 4). Histological
examination with Prussian blue staining demonstrated the
formation of the atherosclerotic plaques in all 15 apoE
2/2 mice.
Of the evaluation of BMC-mediated IL-10 gene therapy of
atherosclerosis, histological quantitative measurements showed
that the mean NWI of animal group I was significantly lower than
those of control animal group II and group III (P,0.05), while
there was no significant difference on the mean NWIs between the
animal groups II and III (Fig. 5).
Discussion
BMCs can differentiate into vascular cells that participate in the
formation of different types of atherosclerotic plaques and
transplant-associated vasculopathy [3,4]. Intracellular MR con-
trast agents, such as Feridex or motexafin gadolinium, can be used
to label different types of cells, so that the cells become MR-
detectable [18–20]. Recent development of a BMC-mediated,
plaque-specific MRI technique enables monitoring of BMCs
trafficking to atherosclerotic lesions [12,21]. A more recent study
demonstrated the possibility of co-transferring BMCs with a green
fluorescent protein (GFP) gene and an intracellular T1-MR
contrast agent [21]. To the best of our knowledge, the current
study represents the first attempt to validate the feasibility of using
in vivo MRI to track the recruitment of BMCs, which were co-
transferred with a therapeutic gene (IL-10 gene) and a T2- MR
Figure 5. Representative histologic images of ascending aorta with measurements of normalized wall indexes (NWI) among three
groups. (A) Mouse group I, transplanted with IL-10/Feridex-BMCs. (B) Group II, transplanted with Feridex-BMCs. (C) Group III with no cell
transplantation. Yellow dotted lines and black dotted lines outline the measured aortic wall area. Atherosclerotic plaques are clearly seen in groups II
and III (B and C). 12.56. Bar: 200 mm. (D) Comparison of NWIs among the three groups, demonstrating that the mean NWI of group I is significantly
lower than those of the control group II and group III (* P,0.05), with no significant difference between two control groups II and III.
doi:10.1371/journal.pone.0024529.g005
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prevention of atherosclerosis.
In this study, through serial in vitro experiments we first
evaluated the possibility of simultaneously transducing and
labeling BMCs with IL-10 genes and Feridex, which confirmed
the achievements of high cell viability and labeling efficiency, as
well as IL-10 expression efficiency ($90%). Subsequently, via
serial in vivo experiments using atherosclerotic apoE
2/2 mouse
models, we successfully validated the feasibility of using in vivo
MRI to track and localize the IL-10/Feridex-BMCs that migrated
to the atherosclerotic aortic walls, where T2-MRI showed signal
voids of the aortic walls due to Feridex-created artifacts from the
recruited Feridex-BMCs in atherosclerotic plaques. The MRI
findings were confirmed by subsequent histology correlations.
One of the essential strategies in the management of
atherosclerotic cardiovascular disease is developing new preven-
tative approaches to inhibit the progress of multiple and diffuse
atherosclerosis. Transplantation of SPCs expressing IL-10 genes,
as reported in the current study, represents an effort for such
technical development. IL-10 is a pleiotropic cytokine, which is
produced primarily by macrophages and lymphocytes. Due to its
anti-inflammatory and anti-apoptotic properties, IL-10 has been
proven to be anti-atherogenic and atheroprotective [22,23]. The
potential anti-atherogenic mechanisms of IL-10 genes include (i)
modulating the signals between two subpopulations of lymphocyte
T helper cells to inhibit the production of proinflammatory
cytokines [24,25]; (ii) diminishing apoptotic activity within the
plaques to decrease the formation of the necrotic cores [22,26,27];
(iii) inhibiting the synthesis of metalloproteinases and stimulating
the production of its inhibitors to promote the stabilities of
atherosclerotic plaques [10,28]; and (iv) modulating lipid metab-
olisms by enhancing both uptake and efflux of cholesterol in
macrophage foam cells [22,29]. In the present study, we have
initially confirmed the potential role of BMC-mediated IL-10 gene
delivery in preventing the progression of atherosclerosis, with
histological evidence showing that the NWI is significantly lower in
the study group with transplantation of IL-10 BMCs in
comparison to the control groups transplanted with Feridex-
BMCs or without BMC transplantation.
Further efforts need to focus on optimizing the protocol to
obtain the best time-points for cell transplantation, the peak of cell-
mediated IL-10 gene expression, and MR imaging. This new
approach only allows us to confirm the successful recruitment of
IL-10/Feridex BMCs to atherosclerotic plaques. Further develop-
ment of a method for in vivo estimating the functions of these
transplanted gene-cells after their recruitment to atherosclerotic
plaques is warranted.
In conclusion, this study has confirmed the possibility of using in
vivo MRI to track IL-10/Feridex-BMCs migrated to atheroscle-
rotic lesions, where IL-10 genes function to prevent or slow the
progression of atherosclerosis. This technique may open a new
avenue for treatment of atherosclerotic cardiovascular diseases
using MR-integrated, BMC-mediated IL-10 gene therapy.
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